NCT04191499 2026-03-17INAVO120Hoffmann-La RochePhase 2/3 Active not recruiting325 enrolled 14 charts 1 FDA
NCT03006172 2026-03-11To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast CancerGenentech, Inc.Phase 1 Active not recruiting200 enrolled
NCT04449874 2026-02-12A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C MutationGenentech, Inc.Phase 1 Active not recruiting498 enrolled